Apixaban and rivaroxaban's physiologically‐based pharmacokinetic model validation in hospitalized patients: A first step for larger use of a priori modeling approach at bed side
Authors:
- Jean TerrierJTJean Terrier
- Frédéric GasparFGFrédéric Gaspar
- Camille LenoirCLCamille Lenoir
- Pierre FontanaPFPierre Fontana
- for the OptimAT study groupFGfor the OptimAT study group
Open Access
- 4 October 2023
- journal article
- research article
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 12 (12) , 1872-1883
Abstract
When used in real‐world conditions, substantial interindividual variations in direct oral anticoagulant (DOAC) plasma concentrations are observed for a given dose, leading to a risk of over‐ or under‐exposure and clinically significant adverse events. Physiologically‐based pharmacokinetic (PBPK) models could help physicians to tailor DOAC prescriptions in vulnerable patient populations, such as those in the hospital setting. The present study aims to validate prospectively PBPK models for rivaroxaban and apixaban in a large cohort of elderly, polymorbid, and hospitalized patients. In using a model of geriatric population integrating appropriate physiological parameters into models first optimized with healthy volunteer data, observed plasma concentration collected in hospitalized patients on apixaban (n = 100) and rivaroxaban (n = 100) were adequately predicted (ratio predicted/observed area under the concentration curve for a dosing interval [AUCtau] = 0.97 [0.96–0.99] geometric mean, 90% confidence interval, ratio predicted/observed AUCtau = 1.03 [1.02–1.05]) for apixaban and rivaroxaban, respectively. Validation of the present PBPK models for rivaroxaban and apixaban in in‐patients represent an additional step toward the feasibility of bedside use.Keywords
This publication has 39 references indexed in Scilit:
- Coadministration of ticagrelor and ritonavir: Toward prospective dose adjustment to maintain an optimal platelet inhibition using the PBPK approachClinical Pharmacology & Therapeutics, 2016
- Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory AcceptanceCurrent Pharmacology Reports, 2016
- Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy SubjectsClinical Therapeutics, 2015
- Clinical Pharmacokinetic and Pharmacodynamic Profile of RivaroxabanClinical Pharmacokinetics, 2013
- Development of a Paediatric Population-Based Model of the Pharmacokinetics of RivaroxabanClinical Pharmacokinetics, 2013
- Characterization of Efflux Transporters Involved in Distribution and Disposition of ApixabanDrug Metabolism and Disposition, 2013
- Utility of a physiologically–based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug–drug–disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practiceBiopharmaceutics & Drug Disposition, 2012
- In Vitro and In Vivo P-Glycoprotein Transport Characteristics of RivaroxabanThe Journal of Pharmacology and Experimental Therapeutics, 2011
- Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterionsJournal of Pharmaceutical Sciences, 2006
- Drug metabolism and ageingBritish Journal of Clinical Pharmacology, 2004